These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6872269)

  • 1. Skin thickness in patients with acromegaly and Cushing's syndrome and response to treatment.
    Ferguson JK; Donald RA; Weston TS; Espiner EA
    Clin Endocrinol (Oxf); 1983 Apr; 18(4):347-53. PubMed ID: 6872269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone status following treatment for Cushing's syndrome.
    Hughes NR; Lissett CA; Shalet SM
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):61-6. PubMed ID: 10468966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian profile of serum melatonin in Cushing's disease and acromegaly.
    Piovesan A; Terzolo M; Borretta G; Torta M; Buniva T; Osella G; Paccotti P; Angeli A
    Chronobiol Int; 1990; 7(3):259-61. PubMed ID: 2268888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
    Tzanela M; Karavitaki N; Stylianidou C; Tsagarakis S; Thalassinos NC
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):309-14. PubMed ID: 15008995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian profile of serum melatonin in patients with Cushing's syndrome or acromegaly.
    Terzolo M; Piovesan A; Alì A; Codegone A; Pia A; Reimondo G; Torta M; Paccotti P; Borretta G; Angeli A
    J Endocrinol Invest; 1995 Jan; 18(1):17-24. PubMed ID: 7759780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone deficiency in treated acromegaly and active Cushing's syndrome.
    Formenti AM; Maffezzoni F; Doga M; Mazziotti G; Giustina A
    Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):79-90. PubMed ID: 28477735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma ACTH and cortisol responses to TRF, vasopressin or hypoglycemia in cushing's disease and nelson's syndrome.
    Krieger DT; Luria M
    J Clin Endocrinol Metab; 1977 Feb; 44(2):361-8. PubMed ID: 190254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?
    Loli P; Boccardi E; Branca V; Bramerio M; Barberis M; Losa M; Terreni MT; Lodrini S; Pollo B; Vignati F
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):433-9. PubMed ID: 9876339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
    Leal-Cerro A; Venegas E; Garcia-Pesquera F; Jimenez LM; Astorga R; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
    Giustina A; Bossoni S; Bodini C; Ferrari C; Pizzocolo G; Scalvini T; Schettino M; Wehrenberg WB
    Horm Res; 1991; 35(3-4):99-103. PubMed ID: 1806475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedside assessment of skin-fold thickness. A useful measurement for distinguishing Cushing's disease from other causes of hirsutism and oligomenorrhea.
    Corenblum B; Kwan T; Gee S; Wong NC
    Arch Intern Med; 1994 Apr; 154(7):777-81. PubMed ID: 8147682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of blood from the inferior sinus petrosus in patients with Cushing syndrome and acromegaly].
    Frey H; Torjesen PA; Enge IP; Stiris MG; Reinlie S
    Tidsskr Nor Laegeforen; 1994 Aug; 114(19):2257-61. PubMed ID: 7992292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic studies of the thymus in acromegaly, diabetes mellitus, and Cushing's syndrome.
    Souadjian JV; Molnar GD; Silverstein MN; Titus JL
    Metabolism; 1970 Jun; 19(6):401-5. PubMed ID: 5444243
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion.
    Carroll PV; Monson JP; Grossman AB; Besser GM; Plowman PN; Afshar F; Savage MO
    Clin Endocrinol (Oxf); 2004 Feb; 60(2):169-74. PubMed ID: 14725677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.